Targeted radiation drug shows promise for tough brain tumors
NCT ID NCT07655869
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing a new radioactive drug, [177Lu]Lu-DOTA-EB-RGD2, in 24 patients with recurrent high-grade glioma, a fast-growing brain cancer. The drug is designed to seek out and deliver radiation directly to tumor blood vessels. It can be given through a vein or directly into the brain tumor cavity via a small device under the scalp. The main goals are to check safety, find the best dose, and see if the drug can slow tumor growth.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
A radioactive drug that targets tumor blood vessels, given by IV or directly into the brain tumor cavity
What this could lead to
If it works, this could point toward a new treatment option for recurrent high-grade glioma, a brain cancer with few effective therapies.
What could go wrong
This is a very early Phase 1 trial with only 24 participants, so it is primarily testing safety and dosing. The drug may not shrink tumors or improve survival, and there are risks of serious side effects like brain swelling or seizures.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT GLIOBLASTOMA, IDH-WILDTYPE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Tiantan Hospital, Capital Medical University
RECRUITINGBeijing, Beijing Municipality, 100070, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
RECRUITINGBeijing, Beijing Municipality, 100730, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact